Literature DB >> 2941043

The pharmacokinetics of doxazosin in elderly normotensives.

J Vincent, P A Meredith, H L Elliott, J L Reid.   

Abstract

The pharmacokinetics of doxazosin were studied in 12 normotensive elderly volunteers aged 62-89 years. There was marked inter-individual variability in all the parameters derived but the disposition of doxazosin was similar in both sexes. These results were compared to those of a group of young normotensive volunteers aged 23-39 years studied previously under comparable conditions. The volume of distribution increased significantly with age although the bioavailability and clearance were not significantly different in the two groups. These results suggest that age is unlikely to influence the disposition of doxazosin to a clinically significant extent.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2941043      PMCID: PMC1401032          DOI: 10.1111/j.1365-2125.1986.tb02835.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Pharmacokinetics in the aged: a review.

Authors:  E J Triggs; R L Nation
Journal:  J Pharmacokinet Biopharm       Date:  1975-12

2.  Rapid evaluation of creatinine clearance.

Authors:  K Siersbaek-Nielsen; J M Hansen; J Kampmann; M Kristensen
Journal:  Lancet       Date:  1971-05-29       Impact factor: 79.321

3.  Sex difference in blood levels of some antibiotics.

Authors:  R Scotti
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

4.  Determination of the vasodilator UK33274 by high-performance liquid chromatography using fluorescence detection.

Authors:  P C Rubin; J Brunton; P Meredith
Journal:  J Chromatogr       Date:  1980-11-14

5.  Disposition of antipyrine and phenytoin correlated with age and liver volume in man.

Authors:  B Bach; J M Hansen; J P Kampmann; S N Rasmussen; L Skovsted
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

6.  Aging, total body potassium, fat-free mass, and cell mass in males and females between ages 18 and 85 years.

Authors:  L P Novak
Journal:  J Gerontol       Date:  1972-10

7.  Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding.

Authors:  M J Hayes; M J Langman; A H Short
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

Review 8.  Pharmacokinetics in the elderly.

Authors:  J Crooks; K O'Malley; I H Stevenson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Prazosin disposition in young and elderly subjects.

Authors:  P C Rubin; P J Scott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of prazosin--1985.

Authors:  J Vincent; P A Meredith; J L Reid; H L Elliott; P C Rubin
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

View more
  6 in total

1.  Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.

Authors:  M Chung; V Vashi; J Puente; M Sweeney; P Meredith
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  The pharmacokinetics of doxazosin in patients with hypertension and renal impairment.

Authors:  R M Oliver; J W Upward; A G Dewhurst; R Honeywell; A G Renwick; D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

3.  A double-blind and cross-over comparison of once daily doxazosin and placebo with steady-state pharmacokinetics in elderly hypertensive patients.

Authors:  P J Scott; J Hosie; M G Scott
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.

Authors:  R A Young; R N Brogden
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

Review 5.  Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.

Authors:  B Fulton; A J Wagstaff; E M Sorkin
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

6.  Single-dose and steady-state pharmacokinetics of doxazosin given in combination with chlorothiazide to hypertensive subjects.

Authors:  E L Conway; J J McNeil; L Meng; O H Drummer; L G Howes; K Raymond; W J Louis
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.